Insider Selling: Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $46.08, for a total value of $576,000.00. Following the sale, the insider owned 166,571 shares of the company’s stock, valued at $7,675,591.68. This trade represents a 6.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Timothy Rolph also recently made the following trade(s):

• On Thursday, September 11th, Timothy Rolph sold 553 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.02, for a total value of $23,790.06.
• On Monday, September 8th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.17, for a total value of $552,125.00.
• On Tuesday, August 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.30, for a total value of $616,250.00.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $53.88 on Friday. Akero Therapeutics, Inc. has a 12 month low of $21.34 and a 12 month high of $58.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.66 and a quick ratio of 12.66. The business has a 50 day simple moving average of $47.15 and a 200-day simple moving average of $46.80. The stock has a market capitalization of $4.31 billion, a PE ratio of -26.94 and a beta of -0.29.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.11. During the same period in the previous year, the firm posted ($0.81) EPS. Equities analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AKRO shares. Lifesci Capital lowered Akero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. TD Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating and a $76.00 price objective on the stock. Canaccord Genuity Group lowered Akero Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $73.00 to $54.00 in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akero Therapeutics in a report on Wednesday. Finally, Wall Street Zen lowered Akero Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $73.38.

Institutional Trading of Akero Therapeutics

Several large investors have recently bought and sold shares of AKRO. GAMMA Investing LLC grew its holdings in Akero Therapeutics by 8,057.1% in the first quarter. GAMMA Investing LLC now owns 10,849 shares of the company’s stock valued at $439,000 after purchasing an additional 10,716 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Akero Therapeutics by 4.7% during the first quarter. Rhumbline Advisers now owns 110,687 shares of the company’s stock valued at $4,481,000 after acquiring an additional 5,001 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Akero Therapeutics during the first quarter valued at $297,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Akero Therapeutics by 14.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock valued at $114,000 after acquiring an additional 338 shares during the last quarter. Finally, KBC Group NV acquired a new stake in shares of Akero Therapeutics during the first quarter valued at $120,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.